

Italy

Population 2017

59 million

| Estimates of TB burden*, 2017 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|----------------------------------|
| Mortality (excludes HIV+TB) | 0.34 (0.33–0.34) | 0.57 (0.56–0.58) |
| Mortality (HIV+TB only) | 0.072 (0.036–0.12) | 0.12 (0.06–0.21) |
| Incidence (includes HIV+TB) | 4.4 (3.8–5.1) | 7.4 (6.3–8.6) |
| Incidence (HIV+TB only) | 0.47 (0.27–0.72) | 0.79 (0.46–1.2) |
| Incidence (MDR/RR-TB)** | 0.18 (0.11–0.25) | 0.3 (0.19–0.43) |

Estimated TB incidence by age and sex (thousands)*, 2017

| | 0-14 years | > 14 years | Total |
|---------|------------------|---------------|---------------|
| Females | 0.16 (0.13–0.2) | 1.3 (1–1.5) | 1.4 (1.1–1.7) |
| Males | 0.19 (0.15–0.23) | 2.8 (2.2–3.4) | 3 (2.4–3.6) |
| Total | 0.36 (0.3–0.42) | 4 (3.4–4.7) | 4.4 (3.8–5.1) |

TB case notifications, 2017

| | |
|--|-------|
| Total cases notified | 3 944 |
| Total new and relapse | 3 828 |
| - % tested with rapid diagnostics at time of diagnosis | 0% |
| - % with known HIV status | |
| - % pulmonary | 70% |
| - % bacteriologically confirmed among pulmonary | 80% |

Universal health coverage and social protection

| | |
|--|------------------|
| TB treatment coverage (notified/estimated incidence), 2017 | 87% (75–100) |
| TB patients facing catastrophic total costs | |
| TB case fatality ratio (estimated mortality/estimated incidence), 2017 | 0.09 (0.08–0.11) |

TB/HIV care in new and relapse TB patients, 2017

| | Number | (%) |
|---|--------|-----|
| Patients with known HIV-status who are HIV-positive | | |
| - on antiretroviral therapy | | |

| Drug-resistant TB care, 2017 | New cases | Previously treated cases | Total number*** |
|---|----------------|--------------------------|-----------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases | | | 91 (59–120) |
| Estimated % of TB cases with MDR/RR-TB | 2.8% (1.8–4.3) | 13% (7.7–21) | |
| % notified tested for rifampicin resistance | 67% | 81% | 2 654 |
| MDR/RR-TB cases tested for resistance to second-line drugs | | | 54 |
| Laboratory-confirmed cases | | MDR/RR-TB: 88, XDR-TB: 5 | |
| Patients started on treatment **** | | MDR/RR-TB: , XDR-TB: | |

| Treatment success rate and cohort size | Success | Cohort |
|--|---------|--------|
| New cases registered in 2016 | | |
| Previously treated cases registered in 2016 | | |
| HIV-positive TB cases registered in 2016 | | |
| MDR/RR-TB cases started on second-line treatment in 2015 | | |
| XDR-TB cases started on second-line treatment in 2015 | | |

TB preventive treatment, 2017

| | |
|---|--|
| % of HIV-positive people (newly enrolled in care) on preventive treatment | |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment | |

TB financing, 2018

| | |
|------------------------------------|--|
| National TB budget (US\$ millions) | |
|------------------------------------|--|

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017



■ Females ■ Males □ Incidence

Treatment success rate (%)



— New cases
— Previously treated cases
— HIV-positive — MDR/RR-TB — XDR-TB